4th vaccine dose “likely ineffective” and advisors failed to recommend it for the general Israeli population/ Times of Israel

Without evidence and most likely in a deal with Pfizer, Israel vaccinated 250,000 citizens with a 4th dose of vaccine.  These human guinea pigs have now learned this not only did not help them, but it may be impairing their immune response to COVID, making them more susceptible to infection.  Last Monday Israel had 40,000 new cases, the most ever recorded.

COVID provided the excuse for massive experimentation on humans without preceding them with experiments in animals.  It has to stop.

In his typical disingenuous fashion, Albert Bourla, Pfizer’s CEO, who has access to all medical records of Israel’s 9 million citizens, said,

“I don’t know if there’s a need for a fourth booster. That’s something that needs to be tested. And I know that Israel already started some of these experiments, and we will also conduct some of these experiments to make sure that if needed, we use it,” he said.

“I don’t think we should do anything that is not needed.”

https://www.timesofisrael.com/eu-regulator-skeptical-on-need-for-additional-covid-booster-shot/ 

EU regulator skeptical on need for additional COVID booster shot

As Israel administers fourth dose of vaccine to the elderly and immunosuppressed, EMA official says move likely ineffective

A woman looks on, as a health worker prepares to administer a booster shot of Pfizer COVID-19 vaccine at a community health center in Jakarta, Indonesia, on January 12, 2022. (AP Photo/ Dita Alangkara)

A woman looks on, as a health worker prepares to administer a booster shot of Pfizer COVID-19 vaccine at a community health center in Jakarta, Indonesia, on January 12, 2022. (AP Photo/ Dita Alangkara)

The main medical regulator for the European Union expressed reservations on Tuesday about the efficacy of an additional booster shot, given the evolving nature of the Omicron strain of the coronavirus and its ability to evade current immunization efforts.

“Preliminary results from recently published studies are showing that the vaccine effectiveness against the symptomatic disease is significantly reduced for Omicron and tends to wane over time,” said Marco Cavaleri, head of the Biological Health Threats and Vaccines Strategy division at the European Medicines Agency (EMA).

Israel has opened up access to the fourth dose, or second booster shot, of the vaccine to at-risk groups, such as the immunocompromised and the elderly, and medical workers. So far, over a quarter of a million people in Israel have received the fourth dose of the coronavirus vaccine, according to the Health Ministry.

However, an advisory panel from the Health Ministry on Monday did not approve expanding access to the fourth dose to the wider population.

Israel, like much of the rest of the world, has been seeing record numbers of COVID-19 cases, driven in large part by the rapid spread of Omicron and threatening to overwhelm schoolshospitals, and the economy. According to Health Ministry statistics, the number of daily coronavirus cases topped 40,000 on Monday for the first time since the pandemic began.

The World Health Organization projected Tuesday that, over the next two months, more than half of the people in Europe could catch Omicron. Experts in Israel have estimated that 2-3 million Israelis could end up contracting Omicron before the current wave of coronavirus cases abates.

Israelis receive a dose of the COVID-19 vaccine at a temporary Maccabi health care center in Rehovot, on January 10, 2022. (Yossi Aloni/Flash90)

Calavi warned that fully relying on the fourth dose might not be the best option to mitigate the Omicron wave. “While use of additional boosters can be part of contingency plans, repeated vaccinations within short intervals would not represent a sustainable long-term strategy,” he said.

Furthermore, he said, Omicron could spur a “natural immunity” that, when combined with vaccination efforts, could help lead COVID-19 out of the pandemic phase.

“With the increase of immunity in population — and with Omicron, there will be a lot of natural immunity taking place on top of vaccination — we will be fast moving towards a scenario that will be closer to endemicity,” Calavi said.

Pfizer CEO Albert Bourla echoed the EMA’s recommendation during an interview on Monday with CNBC.

“I don’t know if there’s a need for a fourth booster. That’s something that needs to be tested. And I know that Israel already started some of these experiments, and we will also conduct some of these experiments to make sure that if needed, we use it,” he said.

“I don’t think we should do anything that is not needed.”

Bourla said that Pfizer is already manufacturing a vaccine targeting Omicron, which should be ready for the public’s use in March.

Agencies contributed to this report.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
Scroll to Top